The recent approval by the French Regulatory authorities of Lipiodol/drug emulsions for the visualization, localization and
vectorization of hepaatocellular carcinoma has focussed attention on this therapeutic application of a product originally introduced to the market decades ago as an iodine-based X-ray contrast agent.